23andMe, MondoBiotech Collaborate to Study Genetic Risk for Rare Diseases | GenomeWeb

Consumer genomics firm 23andMe and Switzerland-based MondoBiotech are collaborating on a global research project to uncover the genetic underpinnings of rare diseases, the partners announced last week.

Details of the collaboration are sparse, but the partners said they hope their research will lead to the development of genetic tests that gauge patients’ predisposition to rare disease and help target individuals most likely to respond to drugs made by MondoBiotech.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.